Helix Acquisition Corp.
HLXA
NASDAQ Capital Market13.25
USD
+2.19
- -
CIK
0001821586
ISIN
KYG4444C1024
Return %
Stock
S&P500
1Y
32.77
18.21
3Y
26.31
63.29
5Y
26.31
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Bihua Chen
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 200 Clarendon Street Boston MA United States of America 02116
- IPO Date
- Oct 1, 2020
- CIK
- 0001821586
- Similar Companies
- Business
- Helix Acquisition Corp. (HLXA) operates as a blank check company, or special purpose acquisition company (SPAC), incorporated in the Cayman Islands in 2020 and headquartered in Boston, Massachusetts, with a focus on effecting mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations, primarily targeting opportunities in the biotechnology and healthcare sectors. Sponsored by affiliates of Cormorant Asset Management, LP, the company raised $115 million in its initial public offering in October 2020, with Class A ordinary shares listed on Nasdaq under the HLXA ticker. It does not conduct significant independent operations or offer products or services beyond pursuing and executing a business combination. In April 2022, Helix Acquisition Corp. completed a reverse merger business combination with MoonLake Immunotherapeutics AG, a clinical-stage biopharmaceutical company developing therapies for inflammatory diseases; post-closing, Helix changed its name to MoonLake Immunotherapeutics, and its shares began trading under the ticker MLTX on Nasdaq, with MoonLake shareholders holding the majority stake in the combined entity. The transaction provided MoonLake access to Helix's trust account proceeds and a $115 million PIPE financing commitment from institutional investors, enabling accelerated clinical development of sonelokimab, a tri-specific Nanobody targeting IL-17A/F-driven diseases in dermatology and rheumatology. As of the latest available data in 2025, the HLXA ticker reflects this delisted status following the merger completion, with no active independent operations under the original entity.
Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares
Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Helix Acquisition Corp. with MoonLake Immunotherapeutics AG